#United States #San Rafael #BioMarin #Galafold #POMBILITI

BioMarin Reports Strong Financial Performance in Q1 2026

BioMarin Pharmaceutical Inc., a leader in the biotechnology sector, has unveiled its financial and operational results for the first quarter ended March 31, 2026. This report reflects significant growth and strategic advancements within the company's portfolio.

In a statement, Alexander Hardy, President and CEO of BioMarin, highlighted the successful acquisition of Amicus Therapeutics, which has augmented BioMarin's offerings to include key therapies for patients suffering from Fabry and Pompe diseases. He emphasized the positive impact of adding GALAFOLD and POMBILITI + OPFOLDA to their commercial roster, enhancing the company's growth trajectory in the near to mid-term. The financial results indicate total revenues for the first quarter reaching approximately $766 million—an increase of $21 million compared to the same quarter in 2025.

BioMarin's optimistic guidance for the full year 2026 stands between $3.825 billion and $3.925 billion, projecting an accelerated growth rate of 20% year-over-year at the midpoint. The soaring revenues stem from the robust demand for their enzyme therapies, particularly VIMIZIM, NAGLAZYME, and PALYNZIQ. The first quarter also saw PALYNZIQ, which was recently relaunched post-label expansion for adolescents, contribute significantly to revenue.

Financial Highlights

BioMarin's key financial metrics for Q1 2026 include:

• - GAAP Net Income: $106 million, a decline from $186 million in Q1 2025.
• - Non-GAAP Income: Registered at $149 million, down from $221 million previously.
• - GAAP Diluted EPS: Notably decreased to $0.54 from $0.95 in the prior year.

These fluctuations in net income and earnings per share are primarily attributed to increased investments in the company's operations and marketing efforts, especially following the Amicus acquisition. BioMarin has significantly ramped up its spending on Research and Development (R&D) and Selling, General, and Administrative (SGA) expenses as part of their growth strategy.

Despite these challenges, the total number of patients being treated with BioMarin's therapies continues to rise, with VOXZOGO users increasing by more than 20% year-over-year. The company is also progressing with its pipeline, looking forward to upcoming data readouts from various Phase 3 studies in the upcoming months

Innovations and Future Outlook

In terms of product innovation, BioMarin secured FDA approval for PALYNZIQ for patients over 12 with phenylketonuria (PKU), alongside other potential approvals expected for the EU market this year. Additional data from ongoing clinical trials for BMN 351, which targets muscular dystrophy, presented promising results indicating improvements in muscle health and overall outcomes.

Furthermore, BioMarin plans to increase its investments in innovation and ramp up clinical development across its product offerings. As they remain focused on expanding their commercial landscape, BioMarin anticipates continuing to forge ahead with significant contributions expected from the Amicus Therapeutics acquisition.

Conclusion

As BioMarin Pharmaceutical Inc. navigates the complex landscape of biopharmaceuticals, their strong Q1 performance illustrates their commitment to providing varied treatments for rare diseases. The strategic expansions and robust patient enrollments highlight a resilient demand for BioMarin's innovative therapies, setting the stage for future growth and advancements in patient care. Stakeholders are invited to join a conference call today, May 4, 2026, at 4:30 p.m. ET, where they will discuss these results and offer insights into future directions for the company.